Podcasts about treatments

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Matthew G. Bowles, PharmD, MBA, CSP, Pharmacy Clinical Team Lead with Vanderbilt Specialty Pharmacy, Vanderbilt Health, and lead author on the study “Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey,” published February 2025 in the Journal of Managed Care & Specialty Pharmacy. They discuss the reasons for conducting and results of the study, as well as the impacts the study may have on specialty and managed care pharmacy.

My new website that links to everything: SARCASTICRECOVERY.COMFollow me on Instagram.New, beautiful meditation channel on YouTube, 11TH STEP CHANNEL.

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Send me a DM here (it doesn't let me respond), OR email me: imagineabetterworld2020@gmail.comToday I'm honored to introduce you to: Owner and founder of Koinonia Counseling Center, Licensed Professional Counselor, ISSTD member, survivor advocate, support, and helper, content creator, educator., proud wife and loving mother, documentary and true crime lover, and a woman single-handedly changing how the world sees and understands Dissociative Identity Disorder: Sara Rice M.A., LPC-SSara is a beacon of compassion and unyielding dedication, a mental health warrior whose entire existence is devoted to empowering RAMCOA survivors and igniting profound healing amid life's darkest storms. As a certified supervisor for licensed professional counselors and the steadfast wife of an Army veteran for over a decade, she draws from an infinite reservoir of empathy and unbreakable resilience. A Mother to five radiant souls, she masterfully orchestrates a vibrant family symphony while pouring her heart into her clients and her insatiable quest for wisdom.With a master's degree in counseling from Liberty University and a doctorate in traumatology on the horizon, Sara embodies relentless pursuit of mastery in trauma and mental health. Her trauma-informed sanctuary isn't just a practice - it's a sacred haven of hope, guiding those who've endured the unimaginable toward light and rebirth. Her gift for connection? A profound grasp of mental health's intricate tapestry, fused with genuine, soul-deep care for every unique journey. This isn't mere work—it's a divine calling to elevate, empower, and resurrect.Her mastery of DID's complexities, her boundless compassion for the RAMCOA community, and her courageous defiance in voicing truths most professionals flee make her a true hero—a luminary we must rally behind, learn from, and celebrate.The first time Sara was on, we discussed Sara's story and how she got into working with RAMCOA survivors as well as her advocacy work, and we also discussed dissociation, Dissociative Identity Disorder, and some of the nuances of therapy and working with dissociation in a therapeutic setting. Sara's knowledge and passion are so refreshing and paramount in a time when dissociative disorders are still considered rare and where little to education on extreme trauma and dissociation is taught in traditional academia. Sara didn't stop learning after her degree was earned - she was just getting started. And now she is paving the way for dissociation and DID to be heard and learned about outside the classroom, and through her work, she is helping to pioneer treatment and healing for survivors who have been failed over and over again. Today we will be diving deeper into and expanding on this conversation with the hope of providing more tools and information for survivors, those who work professionally with survivors, and those who are supporting survivorsCONNECT WITH SARA: Website: https://www.kccpllc.com/#/TikTok: https://www.tiktok.com/@koinoniacounselingcenter?lang=enYouTube: @KoinoniaCounselingCenter  CONNECT WITH EMMA / THE IMAGINATION: YouTube: https://www.youtube.com/@imaginationpodcastofficialRumble: https://rumble.com/c/TheImaginationPodcastEMAIL: imagineabetterworld2020@gmail.com OR standbysurvivors@protonmail.comMy Substack: https://emmakatherine.substack.com/BUY ME A COFFEE: https://www.buymeacoffee.com/theimaginationVENMO: @emmapreneurCASHAPP: $EmmaKatherine1204All links: https://direct.me/theimaginationpodcastSupport the show

On this episode, Chris & Koi call up some friends to find out if the silent treatment works?

This week Erin shares her new hobby of reading rare books from the 1930s, and Bryan gets back to smoking on the set of a short film in New York. Bryan covers annual polls from YouGov/The Economist and Gallup showing support for gay marriage and trans rights is at its lowest level in the last 10 years. Erin discusses how the NHS in the UK is now including menopause screening in routine health checks, plus how the FDA is removing black box warnings from most menopausal therapy products. To subscribe to Erin's Substack click here. For tickets to Dead Pilots Society on 12/7 in LA click here.See omnystudio.com/listener for privacy information.

If you treat a lot of knee pain, this week's episode is for you.We review a new best-practice guide for patellofemoral pain that pulls together research, patient voices, and expert reasoning into one playbook. But here's the twist: when you blend the data with what patients actually want and what clinicians really do, one deceptively simple priority rises to the top - something many of us already use, but probably not the way this paper suggests.I know we are changing what we do at Champion. Curious what it is and how to sequence everything else around it? Check out this week's podcast episode.Show Notes:Evaluation and Treatment of the KneeBest practice guide for patellofemoral pain based on synthesis of a systematic review, the patient voice and expert clinical reasoningTo see full show notes and more, head to: https://mikereinold.com/practice-guidelines-for-patellofemoral-pain/  Click Here to View My Online CoursesWant to learn more from me? I have a variety of online courses on my website!Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show_____Want to learn more? Check out my blog, podcasts, and online coursesFollow me: Instagram | Twitter | Facebook | Youtube

Dr. Kenneth Levy discusses how every therapist should at least be aware of multiple treatments for Borderline Personality Disorder, DBT, TFP, and so on. They don't need to practice them all, but they should know about them.

In this calming and sensory-rich Pod Snack, Shanta invites you into a world of self-care you may not have explored before — the Japanese Head Spa.More than a beauty trend sweeping social media, this soothing ritual blends scalp care, mindfulness, and nervous system healing into an experience that reconnects you to your body in the gentlest way.Shanta shares how her search to help her 13-year-old son's dry, irritated scalp unexpectedly introduced her to the restorative magic of this tradition. What began as a practical solution became a deeper exploration of intentional touch, presence, and the healing power of slowing down. You'll learn:What truly happens during a Japanese Head SpaWhy this ritual is going viral around the worldThe emotional + physical benefits for stress, scalp health, headaches, and mindfulnessHow scalp care is becoming the new frontier of self-careSimple ways to try a Japanese Head Spa experience at homeHow mindful touch can reset your nervous systemThis episode is a reminder that self-care doesn't always look like spa days or bubble baths. Sometimes it's a warm towel, a slow massage, a nurturing ritual — and the permission to breathe again. Stay until the end for a beautiful affirmation to ground your mind and body.If you try the Japanese Head Spa or create your own at-home ritual, share your experience — Shanta would love to hear from you.Stay authentic. Stay mindful. And keep taking care of you.Host:Instagram: @AuthenticTalks2.0 Email: AuthenticShanta@gmail.com Website: www.AuthenticTalks2.com Facebook: AuthenticTalks2 Youtube: @authentictalkswithshanta7489 #MindfulnessInChaos #AuthenticTalks #ShantaGenerally #InnerPeace #MindfulLiving #PeaceWithin #breathe Become a supporter of this podcast: https://www.spreaker.com/podcast/authentic-talks-2-0-with-shanta--4116672/support.

Oregon consistently ranks near the bottom of the country in terms of access to treatment for substance use disorders. Portland-based Boulder Care seeks to address that by providing telehealth and medically assisted treatment options. The company launched in 2017 and has been based in Portland since 2019. Its aim is to normalize this kind of treatment and make it available in the first days or hours when a person with substance use disorder decides they want to get help. Dr. Honora Englander, who directs the Improving Addiction Care Team (IMPACT) at Oregon Health and Science University, says access to telehealth and medication for opioid use disorder is an important part of addressing the huge and multifaceted problem of substance use disorder. Englander and Strong both participated in the industry-wide AMERSA conference held in Portland last week, and they join us in studio to discuss more about evidence-based approaches to in-patient and out-patient care for people dealing with addiction.

What does comprehensive treatment planning look like, and how can specialists and general dentists design it together? In this episode, Dr. Grant Stucki sits down with Florida general dentist and educator Dr. Vic Martel to unpack the ins and outs of comprehensive treatment planning. Dr. Martel explains why many dentists were never taught comprehensive planning in dental school, how this leads to a reactive mindset, and why slowing down to assess occlusion, periodontal health, joints, and restorative needs as a whole improves outcomes for patients and practices. Together, they explore real-world barriers and practical solutions to comprehensive treatment planning and the importance of surgeon-led education and interdisciplinary planning. Dr. Martel shares how he runs new-patient exams and builds trust with patients while coordinating with specialists. He also explains how investing in your referral network can help a practice grow and how a thoughtful, comprehensive treatment plan makes life easier for everyone on the team. Tune in now!Key Points From This Episode:Comprehensive treatment planning and why many dentists are underprepared.The difference between “tooth fixer” dentistry and being a “physician of the mouth.”Learn how comprehensive treatment planning benefits patients and practices.Find out about the biggest barriers to comprehensive treatment planning. How comprehensive planning impacts case acceptance, treatment, and patient outcomes.Hear how generalists and specialists can work together to design a comprehensive plan. Explore the history behind grand rounds and why it is an effective educational tool.Important considerations around implant solutions and the risk of removal. He shares his comprehensive dental exam setup and his overall approach. Discover how shared plans improve coordination, referrals, and patient confidence.Final takeaways and why dentists should focus on educating their referral network.Links Mentioned in Today's Episode:Dr. Victor Martel on LinkedIn — https://www.linkedin.com/in/victor-martel-dmd-91431922/ Dr. Victor Martel on Instagram — https://www.instagram.com/drvicmartel/ Dr. Victor Martel Email Address — martelacademy@gmail.com Dr. Victor Martel Phone Number — 561 602 7222 Martel Academy — https://martelacademy.com/ Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059

Learn More About Dr. Gina Williams at: https://www.facebook.com/share/xPBoeiz4gzhJGB4L/?mibextid=qi2Omghttps://youtube.com/@drgina_dpt?si=rmiLiZKl0a3wmb5s Listen to her podcast at: https://youtube.com/@drgina_dpt?si=rmiLiZKl0a3wmb5s Show notes:

Karla Gess's daughter Kadence had been limping on her right leg for several weeks, and each time Karla or Kadence's father Jarret would take her to the emergency room, her limping would be dismissed and the only thing that she was told was to take Motrin. Finally a Pediatric Nurse saw Kadence, thought her color seemed off and ordered labs, which led to her diagnosis of Stage 4 Neuroblastoma. Kadence is now 5 years old and has been battling this form of Pediatric Cancer for 17 months with at least one year of treatment on the horizon.

Identification of Atrial Fibrillation (A-Fib) & Atrial Flutter on the ECG and the treatment of unstable and stable SVT patients with A-Fib/Flutter.The ECG characteristics of A-Fib and A-Flutter.Recognition and treatment of unstable patients in A-Fib/Flutter with rapid ventricular response (RVR).Suggested energy settings for synchronized cardioversion of unstable patients with a narrow complex tachycardia.Team safety when cardioverting an unstable patient in A-FIB/Flutter.Adenosine's role for stable SVT patients with underlying atrial rhythms.Treatment of stable patients in A-Fib/Flutter with RVR.For other medical podcasts that cover narrow complex tachycardias, visit the pod resource page at passacls.com.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://nationaldrugcard.com/ndc3506/Pass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Transforming your health is more fun with friends! Join Chef AJ's Exclusive Plant-Based Community. Become part of the inner circle and start simplifying plant-based living - with easy recipes and expert health guidance. Find out more by visiting: https://community.chefaj.com/ ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Please get the book here now! To get a copy signed by Dr. Goldhamer: https://www.healthpromoting.com/can-fasting-save-your-life To buy on Amazon: https://www.amazon.com/dp/1570674191?linkCode=ssc&tag=onamzchefajsh-20&creativeASIN=1570674191&asc_item-id=amzn1.ideas.1GNPDCAG4A86S&ref_=aip_sf_list_spv_ofs_mixed_d_asin Dr. LIsle and Dr. Goldhamer's book The Pleasure Trap: https://www.amazon.com/dp/1570671974?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570671974&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Dr. Alan Goldhamer is the co-founder of TrueNorth Health Center, a state-of-the-art facility that provides medical and chiropractic services, psychotherapy and counseling, as well as massage and bodywork. He is also director of the Center's groundbreaking residential health education program. Dr. Goldhamer has supervised the fasts of thousands of patients. Under his guidance, the Center has become one of the premier training facilities for doctors wishing to gain certification in the supervision of therapeutic fasting. Dr. Goldhamer was the principal investigator in two landmark studies. The first: "Medically Supervised Water-Only Fasting in the Treatment of Hypertension" appeared in the June 2001 issue of the Journal of Manipulative and Physiological Therapeutics. Its publication marked a turning point in the evolution of evidence supporting the benefits of water-only fasting. The second study: "Medically Supervised Water-Only Fasting in the Treatment of Borderline Hypertension," appeared in the October 2002 issue of the Journal of Alternative and Complementary Medicine. Currently, Dr. Goldhamer is directing a team that is developing a prospective study, incorporating random assignment and long-term follow-up on the cost and clinical outcomes in the treatment of diabetes and high blood pressure with fasting and a health-promoting diet. After completing his chiropractic education at Western States Chiropractic College in Portland, Oregon, Dr. Goldhamer traveled to Australia, where he became licensed as an osteopathic physician. He is the author of The Health Promoting Cookbook and co-author of The Pleasure Trap: Mastering The Hidden Force That Undermines Health and Happiness. Dr. Goldhamer is speaking at the NHA Virtual Conference (June 27-30, 2024). Use this link to get your tickets now: https://events.ringcentral.com/events/nha-conference-2024/registration?utm_campaign=Chef+AJ&utm_source=Affiliate For coaching services: https://www.healthpromoting.com/clinic-services/health-services/coaching-services To register for a stay at TrueNorth: https://www.healthpromoting.com/registration https://www.ncbi.nlm.nih.gov/myncbi/toshia.myers.2/bibliography/public/ https://www.healthpromoting.com/store/book/can-fasting-save-your-life https://www.fasting.org

Marty's Position on President Trumps Treatment of Reporters full 512 Thu, 20 Nov 2025 19:23:17 +0000 CStNQ84H1fQzaGo9keLFPMN2tVmVTPwO #emailnewsletter,news,a-newscasts,top picks Marty Griffin #emailnewsletter,news,a-newscasts,top picks Marty's Position on President Trumps Treatment of Reporters On-demand selections from Marty's show on Newsradio 1020 KDKA , airing weekdays from 10 a.m. to 2 p.m. 2024 © 2021 Audacy, Inc. News News News News news News News News News News False https://player.amperwavepodcastin

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

This week we're joined by Dr. Amy Wechsler, the Co-founder & CEO of Spotless, NYC's first-ever walk-in acne clinic! Dr. Wechsler is a double-board certified physician in Dermatology and Psychiatry – one of only a handful in the entire country – giving her a rare understanding of how the mind-body connection directly affects the skin.We get all of the scoop on her groundbreaking “blow dry bar for acne” clinic, along with details on her holistic approach to treating acne. Plus, the good doctor, who penned the book “The Mind-Beauty Connection,” gives us the clinical facts on how your mind and your skin are fundamentally connected – and what to do if your stress is showing up on your face.You'll discover:“Cortisol Face” Dr. Wechsler explains why the TikTok trend is misleading and what sustained stress is actually doing to your skin barrier and collagen supplyAccutane Myths: As a psychiatrist and derm, Dr. Wechsler addresses the decades-long concern that Accutane causes depression. Meet Spotless: Dr. Wechsler explains the need for her new walk-in clinic, which offers everything from steroid pimple shots to after-work extractions."Triangle of Death": Dr. Wechsler shuts down the viral rumor that popping a pimple in the area near your nose can cause a fatal brain infection. Plus, we get the scoop on Dr. Wechsler's upcoming skincare line and a second location coming soon!For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/ Related episodes like this: Meet Sofie Pavitt, The "IRL Face Tuner" Who's Magically Transforming People's SkinPeeping Chanel's Archives, Behind The Skincare Lab Curtain & The Facial Trend You're About to See Everywhere#Sunscreen Dos and Don'ts With Dermatologist Dr. Michelle Henry. Plus! Myth-Busting SPF Headlines PROMO CODES: When you support our sponsors, you support the creation of Breaking Beauty Podcast! QuinceStep into the holiday season with layers made to feel good, look polished, and last—from Quince. Perfect for gifting or keeping for yourself. Go to Quince.com/breakingbeauty for free shipping on your order and 365-day returns. Now available in Canada, too. NutrafolSee thicker, stronger, faster-growing hair with less shedding in just 3-6 months with Nutrafol. For a limited time, Nutrafol is offering our listeners $10 off your first month's subscription and free shipping when you go to Nutrafol.com and enter the promo code BREAKING.CurologyGo to getcanopy.co to save $25 on your Canopy Humidifier purchase today with Canopy's filter subscription. And look for other Canopy products such as the Canopy Bath and Shower Filter. Even better, use code BEAUTY at checkout to save an additional 10% off your Canopy purchase. TIATia is the next-generation women's healthcare platform offering whole-body care, from gynecology and hormone support to aesthetic skin care, with fast appointment availability and acceptance of most PPO insurance plans. Get personalized, evidence-based, long-term solutions for your health by booking an appointment at asktia.com today.Get social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here *Disclaimer: Unless otherwise stated, all products reviewed are gratis media samples submitted for editorial consideration.* Hosts: Carlene Higgins and Jill Dunn Theme song, used with permission: Cherry Bomb by Saya
 Produced by Dear Media Studio See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Replay of RheumNow Live 2025 - Spondyloarthritis Sponsored by AbbVie Featuring:  Dr. Desiree van der Heidje - Advances in Treatment of Spondyloarthritis   Dr. Jennifer Cather - Progress in Hidradenitis Supprativa Dr. Catherine Bakewell - Imaging Evaluation of Spondyloarthritis

In this episode of the MamasteFit YouTube channel, certified nurse midwife Roxanne discusses iron deficiency anemia in pregnancy. She explains the importance of hemoglobin and iron in red blood cells, symptoms of anemia, and the necessity of increased iron due to the doubling of blood volume during pregnancy. Roxanne outlines how iron deficiency anemia is screened through blood tests and indicates hemoglobin and ferritin levels. She discusses potential treatments including dietary changes, iron supplements, and more severe interventions like iron or blood transfusions. Roxanne also shares her personal experience with iron deficiency anemia and offers insights on managing the condition. She emphasizes the importance of detecting and treating iron deficiency anemia to prevent potential complications like postpartum hemorrhage and preterm birth. Check out MamasteFit's online courses and fitness programs for additional support.00:00 Introduction to Iron Deficiency Anemia in Pregnancy00:37 Understanding Anemia and Its Impact01:32 Iron's Role in Pregnancy02:21 Preventing and Screening for Anemia04:52 Symptoms and Diagnosis of Iron Deficiency Anemia06:19 Treatment Options for Iron Deficiency Anemia07:02 Personal Experience and Recommendations09:28 Conclusion and Additional Resources————

The Pasadena Unified School District is facing around 30 million dollars in budget cuts. L.A. county jails scaled back opioid addiction treatment during one of the system's deadliest years on record. And what does this rain mean for fire risk in Southern California. Plus, more from Evening Edition. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comThis LAist podcast is supported by Amazon Autos. Buying a car used to be a whole day affair. Now, at Amazon Autos, you can shop for a new, used, or certified pre-owned car whenever, wherever. You can browse hundreds of vehicles from top local dealers, all in one place. Amazon.com/autosVisit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support the show: https://laist.com

Steve Gruber speaks with Amanda Dixon, Counsel at the Becket Fund for Religious Liberty, about a case currently before the Supreme Court in which Colorado Catholics are asking for equal treatment under the law. They discuss the legal arguments, what this case could mean for religious liberty nationwide, and the broader implications for how faith communities are treated under state and federal regulations.

Schizophrenia is a really challenging illness. There's been a lot of progress made recently, I will note. I've already written about novel treatments like Cobenfy, and using accelerated transcranial magnetic stimulation for negative symptoms and positive symptoms in schizophrenia. One of the most bothersome of those “positive symptoms”—things that shouldn't be there, in someone's mind, but are—are auditory hallucinations. If you imagine having invisible AirPods that are playing a terrible podcast that you'd rather not be listening to, and that everyone else can't hear, you get a sense of how distracting it might be to have auditory hallucinations.In my previous article about the treatment of auditory hallucinations with transcranial magnetic stimulation (TMS), one of my favorite forms of brain stimulation, I highlighted promising results from early studies. Now we have a much larger Study, phase 3 trial, conducted over many years in Germany. We are even at the level of meta-analysis at this point!It's a considerable study:138 adults with treatment-persistent auditory verbal hallucinations and schizophrenia spectrum disorder were randomly assigned (1:1) to receive 15 sessions of active (n=70) or sham cTBS (n=68) administered sequentially as 600 pulses to the left and 600 pulses to the right temporo-parietal cortex over a 3-week period.I called friends of the podcast—Dr. David Garrison, Dr. Will Sauve, and my mom, Vita Muir, to talk through this paper together, and what it might mean for individuals suffering from psychotic disorders. In the meantime, the team at Radial, where we provide such treatment, does some funny, tough-guy faces with our Ampa One system:Thanks for reading! A live-action newsletter event coming up on January 11th in San Francisco: RAMHT 2026 SF. Join us! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thefrontierpsychiatrists.substack.com/subscribe

This week I discuss TNA and Mike Santana losing the title on his first title defense. I look at the TNA/WWE partnership doesn't feel like it's equal. I talk about How Mike might be getting the Sasha Banks treatment where he wins the title but not long title run. Then I discuss all the title changes in the NWA and the updated card for ASE' Wrestling 2nd year anniversary. Then I discuss WWE and Preview AEW's Full Gear. I also give my thoughts about Blood &Guts and more.Sponsored ByPassDat Apparel ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.teepublic.com/user/the-inhaling-potnas⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SmokeKind THCA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://smokekind.com/?ref=bobbie_lucas⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sara Jay's CBDsUse Promo Code: BOBBIE To receive 10% off your order⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://sarajaycbd.com/

On this laugh-out-loud episode of The Ben and Skin Show, Ben Rogers, Jeff “Skin” Wade, Kevin “KT” Turner, and Krystina Ray break down one of the most unintentionally hilarious TV moments of the year: George W. Bush joining Peyton and Eli on ESPN's Manning Cast. From robotic, note-card questions to Bush's deadpan zingers, this segment is pure gold.

This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2025 Fall Congress in Colorado Springs, Colorado:  (00:22) A Discussion of Substance: Supporting Meaningful Improvements in the Lives of Patients Struggling With Substance Use Disorders by Brittany Albright, MD and Hara Oyedeji, DNP, PMHNP-BC (Q&A with Dr. Albright)  (34:08) Nightmares and Brainscapes: Emerging Therapeutic Avenues in the Treatment of PTSD by Lori Davis, MD and Andrew Cutler, MD (Q&A with Dr. Davis)  (47:43) Sex, Pudge, and Eyes That Close: Strategies to Address Common Psychotropic–Induced Tolerability Issues by Leslie Citrome, MD and Andrew Cutler, MD (Q&A with Dr. Citrome)   (55:00) When Less Is More: Strategies for Deprescribing Psychotropic Medications by Jeffrey Strawn, MD and Kari Franson, PharmD, PhD, BCPP (Q&A with Dr. Strawn)  Never miss an episode!

In this episode of The Nurse Practitioner Podcast, Julia Rogers, DNP, APRN, CNS, FNP-BC, FAANP and Christina Cantey, DNP, FNP-C, AACC, CCK discuss the transcatheter revolution in the treatment of valvular heart disease.

Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comIn this compilation episode, Dr. Gabrielle Lyon is joined by the top experts in Testosterone and men's health treatments. You'll learn:Why aging alone doesn't drop T levels and why acquisition of conditions like obesity is the real culprit.Why the standard "low T" cutoff is misleading and why you must check your Free Testosterone.How erectile dysfunction is a sensitive marker of overall health and heart risk.The efficacy of Cialis/Viagra for both erections and cardiac protection, and the risks of unchecked influencer advice on steroids.The direct link between muscle mass, exercise, and sexual function—and why the penis is the "first to go" when overall health declines.Chapter Markers:0:00 - Testosterone is a Brain Hormone0:40 - Debunking the Myth: Male Menopause (Andropause) Doesn't Exist1:33 - The Dangers of Unchecked Influencer Advice on Testosterone3:07 - Defining Testosterone Deficiency: Symptoms vs. Signs5:10 - The Arbitrary Number: Why Guidelines Disagree on Low T8:29 - Free Testosterone: The Most Reliable Indicator of Male Health15:28 - TRT vs. Steroids: Defining the Line and Risks18:59 - The Real Risks of TRT: Infertility and Hematocrit22:36 - The Shocking Backstory: Challenging the Prostate Cancer Myth26:40 - Erectile Dysfunction (ED) and Lifestyle Modification29:21 - Shockwave Therapy for ED: The Science and the Cash Business33:53 - Penile Tissue Atrophy and Venous Leak37:25 - The Role of Muscle Mass, Sarcopenia, and Sexual Function39:41 - The Single Best Marker for Male Health: Erectile Function42:02 - The Science of Cialis and Viagra (PDE5 Inhibitors)45:49 - The Viagra Story: From Heart Drug to ED Cure50:50 - Tadalafil (Cialis) as a Triple-Threat Drug (Cardiac, Urinary, Sexual)53:57 - The Role of Testosterone in Female Sexual Function55:20 - Hypogonadism: Diagnosis, Treatment, and Fertility RiskAbout the guests: Dr. Abraham Morgentaler is an Associate Clinical Professor of Urology at Harvard Medical School and founder of Men's Health Boston. He is an internationally recognized expert in men's health, particularly known for his pioneering work in testosterone therapy. Dr. Morgentaler is credited with reversing the long-held belief that testosterone therapy causes prostate cancer and is the author of several books on men's health. YouTubeLinkedInT4L EducationX/Twitter Dr. Tobias Kohler is the co-founder of the Erectile Restoration Outcomes Study (EROS) penile implant registry. In addition to his clinical and research activities, Dr. Kohler is active in education, providing mentorship to residents and fellows.Mayo Clinic ResearchGateLinkedIn

Los Angeles County's jail system is in the middle of one of its deadliest years on record. According to the L.A. County Sheriff's Department, there have been more than three dozen in-custody deaths so far this year, and many have involved overdoses. Now, new reporting from CalMatters reveals that access to critical opioid addiction treatment has been quietly scaled back. Guest: Cayla Mihalovich, CalMatters The Trump administration is suing California over a new law that bars local and federal law enforcement from wearing masks while on duty. Reporter: Tyche Hendricks, KQED Learn more about your ad choices. Visit megaphone.fm/adchoices

My new website that links to everything: SARCASTICRECOVERY.COMFollow me on Instagram.New, beautiful meditation channel on YouTube, 11TH STEP CHANNEL.

Hi girls! ✨Today's episode is SUCH a treat because I'm sitting down with one of my favorite people in the aesthetics world — Julie Lorenzo, nurse practitioner, expert injector, and the founder of Invest In Your Face in Florida. If you care about your skin, your face, or just feeling like your most confident self, this one is for YOU.Julie and I get into ALL the good stuff: facial balancing, Botox, fillers, skin care, microneedling, and what actually works in real life vs. what Instagram tries to sell you. We are talking tried-and-true, safe, reliable treatments that help you look refreshed — not overfilled, not crazy, not like the AI-generated celebrity face everyone is chasing. Just YOU… but glowing. ✨We're also keeping it real about the emotional side of things — confidence, self-love, inner work, and becoming the woman of your dreams from the inside out. This one feels like sitting with your big sisters and getting the real beauty tea.

Lung cancer is the third most common cancer in the U.S. It's caused by harmful cells in your lungs growing unchecked. Treatments include surgery, chemotherapy, immunotherapy, radiation and targeted drugs. Screening is recommended if you're at high risk. Advances in treatments have caused a significant decline in lung cancer deaths in recent years. ​ Lung cancer is a disease caused by uncontrolled cell division in your lungs. Your cells divide and make more copies of themselves as a part of their normal function. But sometimes, they get changes (mutations) that cause them to keep making more of themselves when they shouldn't. Damaged cells dividing uncontrollably create masses, or tumors, of tissue that eventually keep your organs from working properly. Lung cancer is the name for cancers that start in your lungs — usually in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that start in other places and move to your lungs are usually named for where they start (your healthcare provider may refer to this as cancer that's metastatic to your lungs). ​ There are many cancers that affect the lungs, but we usually use the term "lung cancer" for two main kinds: non-small cell lung cancer and small cell lung cancer.  Other types of cancer can start in or around your lungs, including lymphomas (cancer in your lymph nodes), sarcomas (cancer in your bones or soft tissue) and pleural mesothelioma (cancer in the lining of your lungs). These are treated differently and usually aren't referred to as lung cancer.  (CREDITS: Cleveland Clinic)

In this week's episode I'm joined by coach and counsellor Alix Walker. Topics we discuss: - The hurdles accessing care for an eating disorder- Not feeling 'sick enough'- #Skinnytok, 'what I eat in a day' videos, and navigating social media in recovery- Body image healing- Managing triggersAlix's Instagram: @counsellingwithalixAlix's website: alixwalkercounselling.co.uk

Learn more about Fetch Encore and register here today. On this episode of The Vet Blast Podcast presented by dvm360, Adam Christman, DVM, MBA,  welcomes Kelly Chappell, DVM, DACVIM (Small Animal), to talk about feline infectious peritonitis (FIP). Throughout the episode, Chappell and Christman highlight the current challenges in diagnosing FIP, the effectiveness of the antiviral medication GS-441524 for treating these patients, alternative treatments, and more. 

Nov. 18, 2025- Federal changes to Medicaid eligibility could hinder some New Yorkers from accessing treatment for their drug addiction, according to Allegra Schorr, president of Coalition of Medication-Assisted Treatment Providers and Advocates, who is hoping state policymakers will act in response.

The silent treatment has been around as long as marriage. Which is ironic because cutting off communication is the worst thing you can do. Jim Daly explains why you should talk more, not less, when your marriage hits a rough patch. Support Family Ministry If you enjoyed listening to Focus on the Family Commentary, please give us your feedback.

Iraq War veteran Dr. Timothy Vermillion discusses his harm reduction approach to veteran mental health, trauma therapy, PTSD treatment and suicide prevention. As founder of the Paradise Institute, he explains how EMDR memory therapy helps veterans process combat trauma and move from surviving to thriving. Vermillion shares how quitting smoking is also effective in mental health treatment and veteran suicide prevention. Other topics in this episode include Project Athena, a visual map connecting the memories of those who served in Afghanistan to their coordinates; and “Angel's Glow,” and why it took almost 140 years to understand it.Associate Sponsor of Army-Navy Game presented by USAAVeteran & Military Positive Event Timeline

BUFFALO, NY – November 18, 2025 – A new #review was #published in Oncotarget (Volume 16) on November 14, 2025, titled “Mechanism of anticancer action of bifidobacterium: Insights from gut microbiota.” This review, led by first author Hoang Do and correspondent author Ashakumary Lakshmikuttyamma from Thomas Jefferson University, explores how bifidobacterium, a common probiotic found in the gut, may contribute to cancer prevention and therapy. By analyzing existing studies, the authors highlight the growing importance of gut health in cancer treatment and shed light on how bifidobacterium could complement standard cancer therapies. Bifidobacterium is widely known for promoting digestive health and is often included in fermented foods and dietary supplements. However, emerging evidence suggests it may also play a broader role in immune regulation and cancer defense. The review explains how certain strains of bifidobacterium may enhance the effectiveness of chemotherapy, radiation, and immunotherapy in cancers such as breast, lung, colorectal, and gastric cancers. According to the review, bifidobacterium influences cancer outcomes through several biological mechanisms. It helps regulate immune function by reducing inflammation and supporting the activity of immune cells that target tumors. For instance, strains like B. longum and B. breve have been shown to lower levels of harmful inflammatory markers and boost anti-inflammatory responses. These changes can make cancer treatments more effective while also reducing side effects. “Presence of Bifidobacterium breve in gut microbiota extended the median progression-free survival of NSCLC patients.” The review also discusses how bifidobacterium helps detoxify the body by breaking down cancer-causing compounds and limiting their ability to damage cells. In preclinical studies, the probiotic reduced the activity of enzymes that produce carcinogens and helped in converting food-based substances into cancer-fighting agents. Some strains were even found to suppress genes that promote tumor growth and increase molecules that trigger cancer cell death. The authors emphasize that diet plays a critical role in supporting the growth of bifidobacterium. Foods rich in dietary fiber, especially those containing inulin and oligosaccharides like garlic, onions, or leeks, can help increase its levels in the gut. This suggests that simple dietary changes could not only improve gut health but also support cancer prevention and treatment strategies. Although the review presents compelling evidence, the authors stress the need for more clinical trials to determine how different strains of bifidobacterium affect specific types of cancer. Personalized approaches may be necessary to match the right probiotic strains with individual treatment plans. As research continues to uncover the link between gut microbes and cancer, bifidobacterium stands out as a promising natural ally that could enhance the body's defenses and improve cancer treatment outcomes. DOI - https://doi.org/10.18632/oncotarget.28779 Correspondence to - Ashakumary Lakshmikuttyamma - axl025@jefferson.edu Abstract video - https://www.youtube.com/watch?v=KTWJDAN15lY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28779 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Marty talks about the treatment of TSA agents regarding a potential bonus

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Antonio Bianco is a world-renowned physician-scientist and expert in thyroid physiology and metabolism. In this episode, Antonio explores the complex biology of thyroid hormone production, conversion, and regulation—highlighting how deiodinase enzymes modulate hormone activity at the tissue level and why that matters for interpreting lab results. He discusses the shortcomings of relying solely on TSH as a marker of thyroid function, the ongoing debate around combination therapy with T3 and T4 versus standard T4 treatment, and how genetics, tissue sensitivity, and individual variability influence thyroid hormone metabolism. The conversation also examines how hypothyroidism affects energy, mood, cognition, and longevity; why some patients remain symptomatic despite "normal" labs; and how future research could reshape treatment paradigms. We discuss: How the thyroid produces, stores, and activates hormones like T4 and T3 to finely regulate thyroid activity [2:45]; How fasting alters thyroid hormones to conserve energy [12:45]; Action of the deiodinases: how D1, D2, and D3 enzymes control the activation and inactivation of thyroid hormones [19:15]; The normal function of thyroid hormone and the roles of the hypothalamus, pituitary gland, and deiodinases in maintaining hormonal balance [23:30]; Why understanding thyroid physiology is essential for proper diagnosis and treatment of hypothyroidism [33:45]; Testing for thyroid hormones: understanding free vs. total levels, the limitations of current T3 assays, best practices, and more [36:00]; Genetic and sex-based variability in thyroid hormone regulation and their limited clinical significance [43:45]; Hyperthyroidism: causes, symptoms, diagnosis, and treatment options [46:00]; Hypothyroidism: diagnosis and autoimmune causes of hypothyroidism [56:30]; More on hypothyroidism: diagnostic biomarkers, antibody patterns, and non-autoimmune presentations [1:05:00]; Thyroid hormone replacement therapy [1:15:15]; More on thyroid replacement strategies: exploring the evidence gaps, mortality signals, effects on lipids, and more [1:28:00]; Hypothyroidism basics: causes, antibody implications (including pregnancy), and how to make the diagnosis before choosing therapy [1:35:15]; Thyroid medication: compounded controlled-release T3, brand name versus generic, and what Antonio prescribes to newly diagnosed hypothyroid patients [1:42:45]; Redefining treatment success: why normalizing TSH isn't always enough for patients with hypothyroidism [1:54:45]; Case studies: analysis of two unusual cases of thyroid disease [1:57:00]; Dangers of supplementing with high levels of iodine, and female-specific risk of thyroid disease [2:05:45]; Case study of a patient who presents with elevated TSH but no symptoms [2:09:30]; How future research could reshape treatment, and Antonio's new book called "Rethinking Hypothyroidism" [2:13:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Join The Reality Revolution Tribe

Peripheral neuropathy affects approximately 1% of adults worldwide and can be associated with significant disability. Author Michelle Mauermann, MD, of the Mayo Clinic in Minnesota joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss diagnosis and optimal management of peripheral neuropathy. Related Content: Peripheral Neuropathy

Dr. Mary Talley Bowden is an ear, nose and throat specialist in Houston,Texas, host of her own podcast and author of the upcoming book Dangerous Misinformation: The Virus, the Treatments, and the Lies. She talks her disagreements with members of HHS, shots still not getting pulled off the market, vaccine injured going to Japan, support for Doc Chambers to become next governor of Texas, and much more. PLEASE SUBSCRIBE LIKE AND SHARE THIS PODCAST!!!   Watch Show Rumble- https://rumble.com/v71tsqm-cdc-fda-shots-rfk-malone-tx-politics-and-more-dr.-mary-talley-bowden.html YouTube- https://youtu.be/QdwTUSVdAok   Follow Me X- https://x.com/CoffeeandaMike IG- https://www.instagram.com/coffeeandamike/ Facebook- https://www.facebook.com/CoffeeandaMike/ YouTube- https://www.youtube.com/@Coffeeandamike Rumble- https://rumble.com/search/all?q=coffee%20and%20a%20mike Substack- https://coffeeandamike.substack.com/ Apple Podcasts- https://podcasts.apple.com/us/podcast/coffee-and-a-mike/id1436799008 Gab- https://gab.com/CoffeeandaMike Locals- https://coffeeandamike.locals.com/ Website- www.coffeeandamike.com Email- info@coffeeandamike.com   Support My Work Venmo- https://www.venmo.com/u/coffeeandamike Paypal- https://www.paypal.com/biz/profile/Coffeeandamike Substack- https://coffeeandamike.substack.com/ Patreon- http://patreon.com/coffeeandamike Locals- https://coffeeandamike.locals.com/ Cash App- https://cash.app/$coffeeandamike Buy Me a Coffee- https://buymeacoffee.com/coffeeandamike Bitcoin- coffeeandamike@strike.me   Mail Check or Money Order- Coffee and a Mike LLC P.O. Box 25383 Scottsdale, AZ 85255-9998   Follow Dr. Bowden X- https://x.com/MdBreathe Substack- https://drbowden.substack.com/?nthPub=121 Website- https://breathemd.org/   Sponsors Vaulted/Precious Metals- https://vaulted.blbvux.net/coffeeandamike McAlvany Precious Metals- https://mcalvany.com/coffeeandamike/ Independence Ark Natural Farming- https://www.independenceark.com/

A pedofilia tem sido considerada, pelos discursos sociais, como a ‘mais abjeta' entre as perversões. No discurso médico, é uma patologia e refere-se ao fato de um adulto tomar crianças como objeto sexual. Será a pedofilia um pecado, um crime, uma doença? E como lidar com ela? Esta é a primeira de duas partes.Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.>> OUÇA (52min 52s)* PARTICIPAÇÕES ESPECIAISSvetlanna, ou Lanna, é trabalhadora sexual há 8 anos, voluntária no NEP (Núcleo de Estudos da Рrostituição em Porto Alegre), "putativista". No Twitter: @sv3tlannaJuliana Molina Constantino, psicóloga clínica, forense, escritora e educadora. Na clínica trabalha com adultos vítimas de abuso sexual infantil; na justiça atua conduzindo Depoimentos Especiais e realizando Perícias Psicológicas de crianças e adolescentes em processos de apuração de violência de todos os tipos, mas, principalmente a sexual. No Instagram: @psijuconstantino*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*APOIO: INSIDERIlustríssima ouvinte, ilustríssimo ouvinte do Naruhodo, Seguimos firmes e fortes na Black November INSIDER,  a maior promoção da história da marca e o mês mais feliz para quem gosta de se vestir de maneira inteligente! Você já deve ter percebido como as condições do tempo andam malucas: amanhece frio, depois esquenta, depois esfria de novo, quando não chove entre uma coisa e outra...Sabe qual a solução ideal para dias assim? A Tech Long Sleeve Masculina, a camiseta tecnológica INSIDER com mangas longas.Você tem regulação térmica e toque leve, sem passar calor nem passar frio: é garantia de performance em qualquer estação.Na Black November INSIDER, elas podem sair com até 50% de desconto,  combinando o cupom NARUHODO com os descontos do site.E você pode aproveitar ainda mais a promoção: entrando no canal de WhatsApp da INSIDER, onde acontecem as FLASH PROMOS, com descontos ainda maiores, por tempo super limitado.Então não deixe pra depois e entre agora mesmo no grupo de Zap no link:https://creators.insiderstore.com.br/NARUHODOWPPBFOu clique no link que está na descrição deste episódio.INSIDER: inteligência em cada escolha.#InsiderStore*REFERÊNCIASPedofilia: revisão médica e repercussões penais https://www.teses.usp.br/teses/disponiveis/2/2136/tde-10042024-121635/en.phpOs árbitros do desejo e os enteados da natureza: controvérsias e ontologias sobre a categoria pedofilia em torno do DSM - 5 https://www.bdtd.uerj.br:8443/handle/1/19240Aspectos Psicológicos dos Protagonistas de Incestohttps://bdtd.ucb.br:8443/jspui/bitstream/123456789/1884/1/Texto%20Completo.pdfParafilias: uma classificação fenomenológicahttps://actaspsiquiatria.es/index.php/actas/article/download/564/821A Review of Academic Use of the Term “Minor Attracted Persons”https://journals.sagepub.com/doi/10.1177/15248380241270028Sexual interest in children among an online sample of men and women: prevalence and correlateshttps://pubmed.ncbi.nlm.nih.gov/24215791/Correlates and moderators of child pornography consumption in a community samplehttps://pubmed.ncbi.nlm.nih.gov/24088812/PSIQUIATRIA E PEDOFILIA: A ORGANIZAÇÃO B4U-ACT E O DIREITO À SAÚDE MENTAL DAS PESSOAS ATRAÍDAS POR MENORES (MAPS)https://proceedings.science/abrascao-2022/trabalhos/psiquiatria-e-pedofilia-a-organizacao-b4u-act-e-o-direito-a-saude-mental-das-pesThe DSM and the Stigmatization of People who Are Attracted to Minorshttps://www.researchgate.net/profile/Richard-Kramer-10/publication/365993590_The_DSM_and_the_Stigmatization_of_People_who_Are_Attracted_to_Minors/links/638bd5d7ca2e4b239c8896e1/The-DSM-and-the-Stigmatization-of-People-who-Are-Attracted-to-Minors.pdfChanging public attitudes toward minor attracted persons: an evaluation of an anti-stigma intervention https://www.tandfonline.com/doi/abs/10.1080/13552600.2020.1863486?casa_token=iK-wFTzYUbYAAAAA:UmI5w_4dc4d4C9FU9Z1OCpTp5oVb1CkeC1ygV8rg94GSUCUVG886jSpFi6sD_c8uDJQm4gQudZBIQualitative Analysis of Minor Attracted Persons' Subjective Experience: Implications for Treatment https://www.tandfonline.com/doi/abs/10.1080/0092623X.2022.2126808?casa_token=uNwM4nBfx9UAAAAA:Jo75nZFTKEtnYsLlbO2k0hBMaSc5iUC2a2hrGyWF_C5kRNI-ghibqhF01eZPhAv8ygWg-OHWAPyfBeing Sexually Attracted to Minors: Sexual Development, Coping With Forbidden Feelings, and Relieving Sexual Arousal in Self-Identified Pedophiles https://www.tandfonline.com/doi/full/10.1080/0092623X.2015.1061077?src=recsysA Long, Dark Shadow: Minor-Attracted People and Their Pursuit of Dignityhttps://books.google.com.br/books?hl=en&lr=&id=SksqEAAAQBAJ&oi=fnd&pg=PP9&dq=(MAPS)+attracted+by+minors&ots=h0RKV2g6vr&sig=39-uleVMpIgO4bkjPKShVScmfh0&redir_esc=y#v=onepage&q=(MAPS)%20attracted%20by%20minors&f=falseMisrepresenting the “MAP” Literature Does Little to Advance Child Abuse Prevention: A Critical Commentary and Response to Farmer, Salter, and Woodlockhttps://journals.sagepub.com/doi/full/10.1177/15248380251332197Outpatient Therapists' Perspectives on Working With Persons Who Are Sexually Interested in Minorshttps://link.springer.com/article/10.1007/s10508-022-02377-6The Terminology of “Minor Attracted People” and the Campaign to De-stigmatize Paedophilia Originated in Pro-pedophile Advocacyhttps://journals.sagepub.com/doi/full/10.1177/15248380251332198A Profile of Pedophilia: Definition, Characteristics of Offenders, Recidivism, Treatment Outcomes, and Forensic Issueshttps://www.mayoclinicproceedings.org/article/S0025-6196(11)61074-4/abstracthttps://linkinghub.elsevier.com/retrieve/pii/S0025619611610744Pedophilia and Sexual Offending Against Childrenhttps://www.apa.org/pubs/books/4317491Intervention Needs in Prison With Pedophile Inmateshttps://www.papelesdelpsicologo.es/pii?pii=3027Child molester or paedophile? Sociolegal versus psychopathological classification of sexual offenders against children https://www.tandfonline.com/doi/full/10.1080/13552600802133860School sex education, a process for evaluation: methodology and results https://academic.oup.com/her/article-abstract/11/2/205/628476Teachers' Attitudes and Opinions Toward Sexuality Education in School: A Systematic Review of Secondary and High School Teachers https://www.tandfonline.com/doi/abs/10.1080/15546128.2024.2353708‘Chronophilia': Entries of Erotic Age Preference into Descriptive Psychopathologyhttps://www.cambridge.org/core/journals/medical-history/article/chronophilia-entries-of-erotic-age-preference-into-descriptive-psychopathology/1896C08F07CB5F1A428CEEF3E1104586Biological Factors in the Development of Sexual Deviance and Aggression in Males.https://psycnet.apa.org/record/2006-12464-004Mamilos 123 - Pedofilia (2017)https://open.spotify.com/episode/3RxgeS0ZovQue7lK61TLkiNaruhodo #403 - Por que temos fetiches sexuais?https://www.youtube.com/watch?v=C-ET1nIP6WMNaruhodo #433 - Existe amizade entre homens e mulheres? - Parte 1 de 2https://www.youtube.com/watch?v=EFVaBfGaowgNaruhodo #434 - Existe amizade entre homens e mulheres? - Parte 2 de 2https://www.youtube.com/watch?v=H6D1yCni0rcNaruhodo #437 - O termo "macho alfa" faz sentido? - Parte 1 de 2https://www.youtube.com/watch?v=Qx1z1R_He_cNaruhodo #438 - O termo "macho alfa" faz sentido? - Parte 2 de 2https://www.youtube.com/watch?v=UNKh0Zd3h_kNaruhodo #399 - Assistir à pornografia vicia?https://www.youtube.com/watch?v=vByA0QVSOb8Naruhodo #150 - O que é o "No Fap September"?https://www.youtube.com/watch?v=8yWTngyTq1gNaruhodo #325 - Por que nos apaixonamos por vilões? - Parte 1 de 2https://www.youtube.com/watch?v=o9F4Q_jjF88Naruhodo #326 - Por que nos apaixonamos por vilões? - Parte 2 de 2https://www.youtube.com/watch?v=4gtkstkqpUwNaruhodo #320 - Por que nos identificamos com vilões?https://www.youtube.com/watch?v=ZH5aTG0xeLwNaruhodo #419 - Maconha faz mal? - Parte 1 de 2https://www.youtube.com/watch?v=cvLTh2bKPiQNaruhodo #420 - Maconha faz mal? - Parte 2 de 2https://www.youtube.com/watch?v=F7wVcGvpoGA*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

Send us a textIn the second installment of our Rethinking Phototherapy series, Ben and Daphna welcome Dr. Daniel Rauch, Professor of Pediatrics at the Hackensack Meridian School of Medicine and Division Chief of Pediatric Hospital Medicine and General Academic Pediatrics at Joseph Sanzari Children's Hospital. Dr. Rauch co-authored the AAP technical report on phototherapy and brings a unique perspective on how light therapy should be understood and applied in clinical practice.This conversation reframes phototherapy as a true pharmacotherapy—an intervention that must be delivered in precise doses with attention to wavelength, irradiance, body surface exposure, and treatment duration. Dr. Rauch explains why more light is not always better, how technology has evolved from “easy-bake oven” style lamps to modern LED systems, and why maximizing body surface exposure often matters more than piling on extra light banks. The discussion also touches on cycling strategies, the value and limitations of transcutaneous monitoring, and the potential of home phototherapy to reduce unnecessary hospitalizations while supporting family bonding.Listeners will gain practical insights into the art and science of phototherapy: how to optimize treatment, minimize harm, and communicate clearly with families navigating jaundice management.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

------------------- For our listeners, use the code 'EYECODEMEDIA22' for 10% off at check out for our Premiere Billing & Coding bundle or our EyeCode Billing & Coding course. Sharpen your billing and coding skills today and leave no money on the table! questions@eyecode-education.com https://docs.google.com/forms/d/e/1FAIpQLSdEt3AkIpRrfNhieeImiZBF5lYRIR2aAsl7UqWJ_m2GV6OKEA/viewform?usp=header https://coopervision.com/our-company/... Go to MacuHealth.com and use the coupon code PODCAST2024 at checkout for special discounts  Show Sponsors: CooperVision MacuHealth

Breast cancer can be one of the toughest experiences anyone can face, but it can also be a transformative journey. While both the physical and emotional challenges are daunting, the path to healing offers a chance to rediscover resilience and joy in unexpected ways. Today, we are excited to welcome Aastha Saggar, a stage 3 breast cancer survivor and the founder of Still Strength Wellness, where she helps survivors, patients and caregivers reclaim peace, strength, and purpose. Aastha believes that rebuilding energy and vitality is not just possible but can be a beautiful new beginning. Get ready to be inspired as she shares her personal story, along with practical strategies that will empower our listeners to not only survive but thrive.

Our Love Story, Q&A for CouplesIn this powerful episode of Our Love Story, Dyanna Eisel sits down with us to unpack a story that so many moms quietly live through. A wife shares how arguments with her husband do not end when the words stop. Instead, he drags it out, goes short or silent, and then expects everything to magically go back to normal when he is ready.Dyanna walks us through what is really happening beneath the silent treatment, why blame and shutdown hurt so deeply, and how this kind of conflict can hijack your entire day and your emotional health. We talk about what you can do when you feel like you are always the one absorbing the hurt, how to communicate your needs without escalating the fight, and how couples can begin to repair even when one partner tends to withdraw.If you have ever replayed an argument all day, felt guilty for even bringing something up, or wished you could be less affected by the tension in your home, this conversation is for you. Do not just survive the conflict cycle in your marriage. Learn how to recognize the patterns, protect your heart, and start building a safer emotional connection for you and your partner.Watch now so you are not stuck in the same fight again next week.​​Dyanna Eisel, licensed couples counselor​Facebook: https://www.facebook.com/DyannaEiselTherapyLLCMOMnationFacebook: https://www.facebook.com/MOMnationUSA/​#marriagehelp #relationshipadvice #momlife

Andy Cumpstey and Kate Leslie at the American Society of Anesthesiologists (ASA) Annual Meeting in San Antonio, Texas. They interview Peter Nagele, professor of anesthesiology at the University of Chicago, about his groundbreaking trial on the use of nitrous oxide as a treatment for severe depression. The trial aimed to assess the efficacy of nitrous oxide compared to a placebo and explored different doses (25% vs. 50%). They discusses the study's promising results, the neurobiology of depression, and the potential for a phase three international multicenter trial. This episode also highlights the need for novel treatments for treatment-resistant depression and the importance of collaborative research in advancing medical knowledge.